WISARD

To compare viral load outcomes on DTG/RPV FDC regimen (experimental arm) to continued ART regimen (control arm) at 48 weeks as measured by HIV-1 RNA below or confirmed above 50 copies/Ml.

An open label, Multi Centre, Randomised, Switch Study to Evaluate the virological efficacy over 96 weeks of 2-Drug therapy with DTG/RPV FDC in antiretroviral treatment experienced HIV-1 infected subjects virologically suppressed with NNRTIS resistance mutation K103N.

Key Eligibility Criteria

HIV-1 infected adults aged 18 years or over, virologically suppressed with NNRTIs resistance mutation K103N.

(Subjects who at any time have had the mutations 100I, 101E/P, 106A/M, 138K/G/Q, 181C/I/V, 188L, 190A/S/E/Q, 230L mutations are to be excluded.

Other NNRTI region variants can be included).

Therapeutic Area

HIV

Type of Study

Clinical trial PHASE IIIB

Study Status

Closed

Sponsor

NEAT ID Foundation

Principal Investigator

Professor Paddy Mallon

Contact

Binita.maharjan@ucd.ie